Regeneron

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that innovates, develops, and commercializes life-transforming medicines for serious diseases. Since its founding in 1988 by physician-scientists Leonard S. Schleifer and George D. Yancopoulos, Regeneron has been at the forefront of scientific advancement, demonstrating a commitment to pushing the boundaries of medical innovation. The company's vision is clear: to blend cutting-edge science and technology to create impactful therapies.

With a commitment to patient-centered solutions, Regeneron's product offerings span various therapeutic areas, including ophthalmology, oncology, immunology, and rare diseases. Their proprietary technology platforms, such as the VelociSuite®, are critical in speeding up drug discovery and development by generating optimized fully human antibodies. Moreover, the company's ongoing resolve to leverage genetic insights from the Regeneron Genetics Center has led to a deeper understanding of disease pathways, fostering sustainable progression in personalized medicine. Regeneron's strategic focus on innovation and operational efficiency has resulted in numerous FDA approvals and a robust pipeline aimed at transforming patient care across the globe.